Why the study?
Does low density lipoprotein apheresis improve outcomes in patients with severe/extreme hypertriglyceridemia?
Does low density lipoprotein apheresis improve outcomes in patients with severe/extreme hypertriglyceridemia?
This review discusses the causes and management of severe/extreme hypertriglyceridemia, including the use of LDL apheresis.
Answers are grounded in this paper and cite their sources.
Use of LDL apheresis in severe hypertriglyceridemia warrants caution; leaves open whether it improves outcomes.
Hypertriglyceridemia (HTG) is a feature of numerous metabolic disorders including dyslipidemias, metabolic syndrome, and diabetes mellitus type 2 and can increase the risk of premature coronary artery disease. HTG may also be due to genetic factors (called primary HTG) and particularly the severe/extreme HTG (SEHTG), which is a usually rare genetic disorder. Even rarer are secondary cases of SEHTG caused by autoimmune disease. This review considers the causes of SEHTG, and their management including treatment with low density lipoprotein apheresis and analyzes the original findings.
No takes yet. Share an insight, caveat, or question.
Diakoumakou et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: